Pen Injector Manufacturer

A Familiar Pen Injector at an Affordable Price

The EnvoiTM Pen Injector is a compact and user-friendly pen device designed for the subcutaneous delivery of medication. It is intended to be used for self-administration of injectable medications, including insulin and glucagon-like peptide-1 (GLP-1). The Envoi Pen Injector is an important addition to the Phillips Medisize portfolio, empowering biopharma companies to accelerate the roll out of novel and generic drug treatments with significant economies of scale.

This solution provides the advantages expected from familiar pen designs, while benefiting from decades of our device development expertise and large-volume manufacturing capabilities to reduce the challenge of bringing affordable drugs and delivery devices to market.

Envoi Pen Injector

Offering access to a pen that aligns with cutting-edge devices available today, at an appealing price point, while reducing the cost, time and risk associated with a custom development:

Designed for 3.0 ml and 1.5 ml cartridges

An easy-to-scale platform, currently available for 3 ml cartridges

Designed for patients managing diabetes, growth hormones, fertility and osteoporosis

Benefits of the Envoi Pen Injector

• Combining a compact design with the capability of administering up to 80 IU in a single injection (~152 mm length)
• Featuring a limited elongation (~33 mm) for maximum dosing
• Supporting ease of administration for individuals with small hands or dexterity issues
• Incorporating a flexible design to accommodate fixed and variable dosing requirements
• Targeting relatively low dosing force*
• Handling final assembly for design validation testing (DVT) and production of clinical batches

Backed by Our Proven Experience in

High-Volume / High-Quality Manufacturing

Established Global Footprint Across Three Continents

A User-Friendly Patient Experience

Supporting Your Product Journey, Every Step of the Way

Our comprehensive technical documentation package helps support your U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) submissions. We can provide:

• Technical components’ specifications for development of pen and cartridge assembly lines
• Part build services for stability studies
• Technical dossier for reference in your drug approval applications
• Technical files for pen customizations, if applicable
• Regulatory support in different geographical regions

March 17, 2025

Aria Smart Autoinjector

A compact, simple-to-use and connectivity-enabled injection device featuring a reusable electromechanical drive unit and single-use, disposable cassettes.

March 17, 2025

Pharmaceutical

Expertise and experience to create design strategies for all stages of development, from clinical trials to small- and large-scale commercial production.

*Depending on the cartridge specification – the DVT to assess the actual force

This product has not obtained a CE marking applicable to the health, safety and environmental regulations of the European Union, and has not been reviewed or cleared for use by the U.S. Food and Drug Administration or comparable health regulatory authorities in other jurisdictions.

Envoi™ is a trademark of Phillips Medisize.

Featured Resources

Publication

September 9, 2024

Drug Development and Delivery – Phillips Medisize: Pen Injector Appeals to a Range of Customers

The injection market is currently dominated by pen injectors for insulin delivery, but autoinjectors are becoming more common and in a broader range of indications. Read.

Article

December 12, 2023

Building a Quality Culture to Improve Healthcare Manufacturing

The word “quality” is synonymous with medical, pharmaceutical and diagnostic device design, development and manufacturing. Learn more.

Article

March 17, 2022

Drug Delivery Evolution Drives Complexity in Quality Control

As pen injectors, autoinjectors, on-body injectors and other drug delivery devices grow more complex, quality control becomes more complicated. Learn more.